Skip to content

Illumina新闻发布

年 : 2021

日期 标题
2021-10-15 基因检测产业联盟(上海)正式成立 引领产业发展新时代
2021-10-14 Illumina Appoints Bob Ragusa as Chief Executive Officer (CEO) of GRAIL
2021-10-13 Illumina to Announce Third Quarter 2021 Financial Results on Thursday, November 4, 2021
2021-9-30 Illumina Expands Presence in Latin America
2021-9-27 随机试验表明:全基因组测序有助于改善不同情形危重症婴幼儿的护理
2021-9-15 Illumina Accelerator Invests in Seven Genomics Startups for Third Global Cycle
2021-9-9 因美纳承诺到2050年在全球范围实现温室气体净零排放
2021-9-7 因美纳与默沙东将共同开发和商业化用于识别特定癌症突变的伴随诊断及科研检测产品
2021-8-30 Illumina To Webcast Upcoming Investor Conference
2021-8-18 因美纳完成GRAIL收购,加速普及能够挽救患者生命的多癌种早期检测技术
2021-8-5 因美纳发布2021财年第二季度的业绩报告
2021-8-3 Illumina Donates $1 Million in Sequencing Capabilities to Mumbai to Support Sequencing-Based COVID-19 Surveillance in India
2021-7-28 Illumina to Webcast Upcoming Investor Conference
2021-7-22 Illumina is Committed to Bringing Lifesaving GRAIL Test to People Globally as European Review Process Enters Second Phase
2021-7-13 Illumina to Announce Second Quarter 2021 Financial Results on Thursday, August 5, 2021
2021-6-1 Illumina Supports Nationwide Program across Belgium to Assess Whole Genome Sequencing for Developmental Disorders Diagnosis
2021-5-31 Illumina and Next Generation Genomic Partner to Launch VeriSeq™ NIPT Solution in Thailand
2021-5-27 Illumina To Webcast Upcoming Investor Conference
2021-5-17 Illumina Appoints Susan Tousi as Chief Commercial Officer and Dr. Alex Aravanis as Chief Technology Officer, Head of Research and Product Development
2021-4-29 Illumina To Webcast Upcoming Investor Conference
2021-4-29 Illumina Files Action for Annulment of European Commission’s Decision Asserting Jurisdiction to Review GRAIL Acquisition
2021-4-28 因美纳向全球病原体基因组计划捐赠6000万美元测序设备
2021-4-27 因美纳发布2021财年第一季度的业绩报告
2021-4-22 因美纳与Kartos Therapeutics建立肿瘤领域合作, 共同开发基于新一代测序技术(NGS)的TP53伴随诊断
2021-4-20 Illumina Remains Committed to GRAIL Acquisition to Accelerate Access to Breakthrough Multi-Cancer Early Detection Blood Test
2021-4-5 Illumina Announces Preliminary Revenue for First Quarter Fiscal Year 2021
2021-3-30 Illumina Committed to Pursuing GRAIL Acquisition to Accelerate Access to Breakthrough Multi-Cancer Early Detection Blood Test
2021-3-18 Illumina Announces Board Changes
2021-3-11 Illumina and Harvard Pilgrim Health Care Real-World Evidence Study Demonstrates Cost-Effectiveness of Offering NIPT to All Pregnant Women
2021-3-5 Illumina and R-Pharm Secure Registration for Two Complete IVD Sequencing Platforms in Russia
2021-2-11 Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2020
2021-2-10 Illumina to Webcast Upcoming Investor Conference Presentations
2021-2-8 Illumina加速器在第二轮全球周期中投资了9家基因组初创公司
2021-2-4 Illumina支持在比利时真实环境下评估全景变异分析在晚期癌症中应用潜力的国家级项目
2021-1-31 因美纳与红杉中国在华共推基因组学孵化器
2021-1-25 Illumina to Announce Fourth Quarter & Full Year 2020 Financial Results on Thursday, February 11, 2021
2021-1-20 Illumina Wins Patent Infringement Suit against BGI in the UK
2021-1-16 因美纳NextSeq™550Dx基因测序仪正式上市并完成首台装机
2021-1-11 全新生物信息解决方案将推动大规模多组学研究探索
2021-1-11 因美纳宣布与多家肿瘤领域企业达成全新合作 将推动全面基因组测序分析
2021-1-5 Illumina and Helix Collaborate to Assess Prevalence of New SARS-CoV-2 UK Variant (B.1.1.7) in the US and Develop National Surveillance Infrastructure